Skip to main content
SpringerLink
Log in

Targeting insulin-like growth factor type 1 receptor in cancer therapy

  • Review
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

It is believed that the insulin-like growth factor receptor type 1 (IGF-1R) signaling pathway plays a pivotal role in cancer growth, progression, and resistance to anticancer therapies. Strategies are being developed to block IGF-1R as an anticancer treatment. We reviewed several potential strategies for disrupting the IGF axis. We also reviewed the effects of two drugs that target the IGF-1R: monoclonal antibodies and tyrosine kinase inhibitors. Preliminary results of studies involving these agents provided a foundation for ongoing clinical trials, whose results in the near future will help us understand how to incorporate anti IGF-1R strategies into the current anticancer armamentarium.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505–418

    Article  CAS  PubMed  Google Scholar 

  2. Hankinson SE, Willett WC, Colditz GA et al (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113):1393–1396

    Article  CAS  PubMed  Google Scholar 

  3. Roddam AW, Allen NE, Appleby P et al (2008) Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149(7):461–471

    PubMed  Google Scholar 

  4. Ma J, Pollak MN, Giovannucci E et al (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91(7):620–625

    Article  CAS  PubMed  Google Scholar 

  5. Ouban A, Muraca P, Yeatman T et al (2003) Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 34(8):803–908

    Article  CAS  PubMed  Google Scholar 

  6. Camirand A, Zakikhani M, Young F et al (2005) Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 7(4):570–579

    Article  Google Scholar 

  7. Jones HE, Goddard L, Gee JM et al (2004) Insulin-like growth factor-I receptor signaling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11(4):793–814

    Article  CAS  PubMed  Google Scholar 

  8. Chakravarti A, Loeffler JS, Dyson NJ (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62(1):200–207

    CAS  PubMed  Google Scholar 

  9. Liu B, Fang M, Lu Y et al (2001) Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene 20(15):1913–1922

    Article  CAS  PubMed  Google Scholar 

  10. Sakamoto M, Kondo A, Kawasaki K et al (2001) Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell 14(4):305–315

    CAS  PubMed  Google Scholar 

  11. Shimizu C, Hasegawa T, Tani Y et al (2004) Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol 35(12):1537–1542

    Article  CAS  PubMed  Google Scholar 

  12. Abe S, Funato T, Takahashi S et al (2006) Increased expression of insulin-like growth factor i is associated with Ara-C resistance in leukemia. Tohoku J Exp Med 209(3):217–228

    Article  CAS  PubMed  Google Scholar 

  13. Cappuzzo F, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S et al (2006) Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 17(7):1120–1127

    Article  CAS  PubMed  Google Scholar 

  14. Friedrich N, Haring R, Nauck M et al (2009) Mortality and serum insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. J Clin Endocrinol Metab 94(5):1732–1739

    Article  CAS  PubMed  Google Scholar 

  15. Rowlands MA, Gunnell D, Harris R et al (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124(10):2416–2429

    Article  CAS  PubMed  Google Scholar 

  16. Papadimitrakopoulou VA, Brown EN, Liu DD et al (2006) The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. Cancer Lett 239(1):136–143

    Article  CAS  PubMed  Google Scholar 

  17. Chang YS, Wang L, Suh YA, Mao L, Karpen SJ, Khuri FR et al (2004) Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene 23(39):6569–6580

    Article  CAS  PubMed  Google Scholar 

  18. Baglietto L, English DR, Hopper JL et al (2007) Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 16(4):763–768

    Article  CAS  PubMed  Google Scholar 

  19. Nedic O, Malenkovic V, Dukanovic B et al (2008) Association of elevated IGFBP-1 with increased IGF-II concentration in patients with carcinoma of the liver. Int J Biol Markers 23(4):225–230

    CAS  PubMed  Google Scholar 

  20. Renehan AG, Jones J, Potten CS et al (2000) Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer 83(10):1344–1350

    Article  CAS  PubMed  Google Scholar 

  21. Rikhof B, van Doorn J, Suurmeijer AJ et al (2009) Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour. Ann Oncol 20(9):1582–1588

    Article  CAS  PubMed  Google Scholar 

  22. Lin Y, Jiang T, Zhou K et al (2009) Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol. doi:10.1215/15228517-2008-114

    PubMed  Google Scholar 

  23. Letsch M, Schally AV, Busto R et al (2003) Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc Natl Acad Sci U S A 100(3):1250–1255

    Article  CAS  PubMed  Google Scholar 

  24. Thorner MO, Strasburger CJ, Wu Z et al (1999) Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab 84(6):2098–2103

    Article  CAS  PubMed  Google Scholar 

  25. Schreiber I, Buchfelder M, Droste M et al (2007) Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156(1):75–82

    Article  CAS  PubMed  Google Scholar 

  26. Yin D, Vreeland F, Schaaf LJ et al (2007) Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res 13(3):1000–1009

    Article  CAS  PubMed  Google Scholar 

  27. Divisova J, Kuiatse I, Lazard Z et al (2006) The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat 98(3):315–327

    Article  CAS  PubMed  Google Scholar 

  28. McCutcheon IE, Flyvbjerg A, Hill H et al (2001) Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 94(3):487–492

    Article  CAS  PubMed  Google Scholar 

  29. Goya M, Miyamoto S, Nagai K et al (2004) Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 64(17):6252–6258

    Article  CAS  PubMed  Google Scholar 

  30. Arteaga CL, Kitten LJ, Coronado EB et al (1989) Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84(5):1418–1423

    Article  CAS  PubMed  Google Scholar 

  31. Pollak M (2008) Targeting insulin and insulin-like growth factor signaling in oncology. Curr Opin Pharmacol 8(4):384–392

    Article  CAS  PubMed  Google Scholar 

  32. Munshi S, Hall DL, Kornienko M et al (2003) Structure of apo, unactivated insulin-like growth factor-1 receptor kinase at 1.5 A resolution. Acta Crystallogr D Biol Crystallogr 59(Pt 10):1725–1730

    Article  PubMed  Google Scholar 

  33. Pollak M (2008) Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 22(4):625–638

    Article  CAS  PubMed  Google Scholar 

  34. Hofmann F, Garcia-Echeverria C (2005) Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today 10(15):1041–1047

    Article  CAS  PubMed  Google Scholar 

  35. Cohen BD, Baker DA, Soderstrom C et al (2005) Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751, 871. Clin Cancer Res 11(5):2063–2073

    Article  CAS  PubMed  Google Scholar 

  36. Haluska P, Shaw HM, Batzel GN et al (2007) Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751, 871 in patients with refractory solid tumors. Clin Cancer Res 13(19):5834–5840

    Article  CAS  PubMed  Google Scholar 

  37. Lacy MQ, Alsina M, Fonseca R et al (2008) Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751, 871 in patients with multiple myeloma. J Clin Oncol 26(19):3196–3203

    Article  CAS  PubMed  Google Scholar 

  38. Karp DD, Paz-Ares LG, Blakely LJ et al (2007) Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. 25(18S):7506

  39. Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, Lipton A, Demers L, Leitzel K, Hixon ML, Terstappen LW, Garland L, Paz-Ares LG, Cardenal F, Langer CJ, Gualbert A (2009) Safety, pharmacokinetics and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751, 871) in combination with paclitaxel and carboplatin. J Thorac Oncol. doi:10.1097/JTO.0b013e3181ba2f1d

    Google Scholar 

  40. Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid Tumors. http://clinicaltrials.gov/show/NCT00729833. Accessed 28 Sept 2009

  41. A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks. http://clinicaltrials.gov/show/NCT00728390. Accessed 28 Sept 2009

  42. Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer. http://clinicaltrials.gov/show/NCT00560573. Accessed 28 Sept 2009

  43. Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer. http://clinicaltrials.gov/ct2/show/NCT00678626. Accessed 28 Sept 2009

  44. Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC). http://clinicaltrials.gov/show/NCT00313781. Accessed 28 Sept 2009

  45. Postel-Vinay S, Okuno S, Schuetze S et al (2008) Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma. 20th EORTC–NCI–AACR Symposium on Molecular Targets and Cancer Therapeutics. Proceedings Eur J Cancer 6(12) 2008, abstract 388

    Google Scholar 

  46. Study of CP-751,871 In combination with exemestane in postmenopausal women with Hormone Receptor Positive Advanced Breast Cancer. http://clinicaltrials.gov/show/NCT00372996. Accessed 28 Sept 2009

  47. Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments. http://clinicaltrials.gov/show/NCT00560560. Accessed 28 Sept 2009

  48. Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer (NSCLC). http://clinicaltrials.gov/show/NCT00673049. Accessed 28 Sept 2009

  49. Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology. http://clinicaltrials.gov/show/NCT00596830. Accessed 28 Sept 2009

  50. Burtrum D, Zhu Z, Lu D et al (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63:8912–8921

    CAS  PubMed  Google Scholar 

  51. Rowinsky EK, Youssoufian H, Tonra JR et al (2007) (2007) IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 13(18 Pt 2):5549s–5555s

    Article  CAS  PubMed  Google Scholar 

  52. Higano CS, Yu EY, Whiting SH et al (2007) A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol 25(18 S): abstract 3505

    Google Scholar 

  53. Rothenberg ML et al (2007) Phase I dose-escalation study of the anti-IGF-IR recombinant human IgG1 monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, abstract C84

  54. A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent. http://clinicaltrials.gov/show/NCT00668148. Accessed 28 Sept 2009

  55. Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors. http://clinicaltrials.gov/ct/show/NCT00831844. Accessed 28 Sept 2009

  56. A Study of IMC-A12 in Adrenocortical Cancer. http://clinicaltrials.gov/show/NCT00810537. Accessed 28 Sept 2009

  57. Monoclonal Antibody IMC-A12 and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer. http://clinicaltrials.gov/ct/show/NCT00678223. Accessed 28 Sept 2009

  58. Cixutumumab and Temsirolimus in Treating Young Patients With Solid Tumors That Have Recurred or Not Responded to Treatment. http://clinicaltrials.gov/ct/show/NCT00880282. Accessed 28 Sept 2009

  59. IMC-A12 and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer. http://clinicaltrials.gov/ct/show/NCT00699491. Accessed 28 Sept 2009

  60. Monoclonal Antibody IMC-A12 and Doxorubicin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma. http://clinicaltrials.gov/ct/show/NCT00720174. Accessed 28 Sept 2009

  61. Study of IMC-A12, Alone or in Combination With Cetuximab, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck. http://clinicaltrials.gov/show/NCT00617734. Accessed 28 Sept 2009

  62. Capecitabine and Lapatinib With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV Breast Cancer. http://clinicaltrials.gov/ct/show/NCT00684983. Accessed 28 Sept 2009

  63. Study Using IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer, Following Disease Progression on Docetaxel-Based Chemotherapy. http://clinicaltrials.gov/show/NCT00683475. Accessed 28 Sept 2009

  64. A Study for Safety and Effectiveness of IMCA12 by Itself or Combined With Antiestrogens to Treat Metastatic Breast Cancer in Patients Who Progressed on Antiestrogen Therapy. http://clinicaltrials.gov/show/NCT00728949. Accessed 28 Sept 2009

  65. Mitotane With or Without IMC-A12 in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery. http://clinicaltrials.gov/ct/show/NCT00778817. Accessed 28 Sept 2009

  66. Erlotinib With or Without IMC-A12 in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer. http://clinicaltrials.gov/ct/show/NCT00778167. Accessed 28 Sept 2009

  67. Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer. http://clinicaltrials.gov/show/NCT00769795. Accessed 28 Sept 2009

  68. Multicenter Study of IMC-A12 in Combination With Depot Octreotide in Patients With Carcinoid or Islet Cell Cancer. http://clinicaltrials.gov/show/NCT00781911. Accessed 28 Sept 2009

  69. A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of People With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab (FC-4). http://clinicaltrials.gov/show/NCT00845039. Accessed 28 Sept 2009

  70. A Study to Test IMC-A12 With and Without Other Standard Chemotherapies in Patients With Lung Cancer Who Have Not Received Chemotherapy Before. http://clinicaltrials.gov/show/NCT00870870. Accessed 28 Sept 2009

  71. Beltran P, Mitchell P, Hwang D et al (2007) Inhibition of endocrine IGF-1 signaling in normal murine tissues and human tumor xenografts with AMG 479, a fully human anti IGF-1R monoclonal antibody. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, 2007, abstract A67

  72. Calzone F, Chung YA, Cajulis E et al (2008) Domain-specific mechanisms of receptor inhibition by AMG 479, a fully-human IGF1R targeted antibody. 99th AACR Annual Meeting 2008, abstract 3994

  73. Moody G, Mitchell P, Cajulis E et al (2007) AMG 479, a fully human anti IGF-1 receptor monoclonal antibody, is efficacious against Ewing’s sarcoma and osteosarcoma xenografts. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, 2007, abstract A64

  74. Tolcher AW, Rothenberg ML, Rodon J, et al. A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18 S Suppl; abstr: 3002

  75. Sarantopoulos J, Mita AC, Mulay M et al (2008) A phase IB study of AMG-479, a type 1 insulin-like growth factor receptor (IGF1R) anitbody, in combination with panitumumab (P) or gemcitabine (G). J Clin Oncol 26(15S):3583

    Google Scholar 

  76. A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing’s Family Tumor and Desmoplastic Small Round Cell Tumors. http://clinicaltrials.gov/show/NCT00563680. Accessed on 28 Sept 2009

  77. Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-Sensitive Ovarian Cancer. http://clinicaltrials.gov/show/NCT00719212. Accessed on 28 Sept 2009

  78. A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer. http://clinicaltrials.gov/show/NCT00630552. Accessed on 28 Sept 2009

  79. Panitumumab Combination Study With AMG 102 or AMG 479 in Wild-Type KRAS mCRC. http://clinicaltrials.gov/show/NCT00788957. Accessed on 28 Sept 2009

  80. A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer. http://clinicaltrials.gov/show/NCT00791154. Accessed on 28 Sept 2009

  81. Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer. http://clinicaltrials.gov/show/NCT00807612. Accessed on 28 Sept 2009

  82. AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors. http://clinicaltrials.gov/show/NCT00819169. Accessed on 28 Sept 2009

  83. Amgen Protocol No. 20060362 - A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer. http://clinicaltrials.gov/show/NCT00626106. Accessed on 28 Sept 2009

  84. Phase 2 Safety & Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 vs FOLFIRI in KRAS-Mutant Metastatic Colorectal Carcinoma. http://clinicaltrials.gov/show/NCT00813605. Accessed on 28 Sept 2009

  85. Goetsch L, Gonzalez A, Leger O et al (2005) Recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113:316–328

    Article  CAS  PubMed  Google Scholar 

  86. Atzori F, Tabernero J, Cervantes A et al (2008) A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors. J Clin Oncol 26(15S): abstract 3519

    Google Scholar 

  87. Hidalgo M, Tirado Gomez M, Lewis N et al (2008) A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule. J Clin Oncol 26(15S): abstract 3520

    Google Scholar 

  88. A Study of MK0646 in Breast Cancer Patients. http://clinicaltrials.gov/show/NCT00759785. Accessed on 28 Sept 2009

  89. A Combination Study With MK8669 and MK0646 in Patients With Advanced Cancer. http://clinicaltrials.gov/show/NCT00730379. Accessed on 28 Sept 2009

  90. MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer (IMPACT). http://clinicaltrials.gov/show/NCT00799240. Accessed on 28 Sept 2009

  91. Phase I Imaging Study Evaluating MK0646 in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer. http://clinicaltrials.gov/show/NCT00729742. Accessed on 28 Sept 2009

  92. MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer. http://clinicaltrials.gov/ct/show/NCT00869752. Accessed on 28 Sept 2009

  93. Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET). http://clinicaltrials.gov/show/NCT00610129. Accessed on 28 Sept 2009

  94. MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer. http://clinicaltrials.gov/show/NCT00769483. Accessed on 28 Sept 2009

  95. Study of MK0646 in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer. http://clinicaltrials.gov/show/NCT00614393. Accessed on 28 Sept 2009

  96. Rodon J, Patnaik A, Stein M et al (2007) A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. J Clin Oncol 25(18S):3590

    Google Scholar 

  97. A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors. http://clinicaltrials.gov/show/NCT00560144. Accessed on 28 Sept 2009

  98. A Study of R1507 in Patients With Recurrent or Refractory Sarcoma. http://clinicaltrials.gov/show/NCT00642941. Accessed on 28 Sept2009

  99. A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC). http://clinicaltrials.gov/show/NCT00760929. Accessed on 28 Sept 2009

  100. A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy. http://clinicaltrials.gov/show/NCT00773383. Accessed on 28 Sept 2009

  101. A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer. http://clinicaltrials.gov/show/NCT00796107. Accessed on 28 Sept 2009

  102. A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors. http://clinicaltrials.gov/show/NCT00811993. Accessed on 28 Sept 2009

  103. Maloney EK, McLaughlin JL, Dagdigian NE et al (2003) An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63:5073–5083

    CAS  PubMed  Google Scholar 

  104. Dallas NA, Xia L, Fan F et al (2009) Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 69(5):1951–1957

    Article  CAS  PubMed  Google Scholar 

  105. Descamps G, Gomez-Bougie P, Venot C et al (2009) A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45. Br J Cancer 100(2):366–369

    Article  CAS  PubMed  Google Scholar 

  106. Moreau P, Hulin C, Facon T et al (2007) Phase I study of AVE1642 Anti IGF-1R monoclonal antibody in patients with multiple myeloma. ASH Annual Meeting Abstracts. Blood 11:1166

    Google Scholar 

  107. Tolcher AW, Patnaik A, Till E et al (2008) A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (Insulin like growth factor 1 receptor) antagonist, in patients (pts) with advanced solid tumor (ST). J Clin Oncol 26(15 S): abstract 3582

    Google Scholar 

  108. Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma. http://clinicaltrials.gov/show/NCT00791544. Accessed on 28 Sept 2008

  109. Kolb EA, Gorlick R, Houghton PJ et al (2008) Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 50(6):1190–1197

    Article  PubMed  Google Scholar 

  110. Seraj J, Tsai M, Seiberling M et al (2007) Evaluation of safety and pharmacokinetics of a fully human IGF-1 receptor antibody, SCH 717454, in healthy volunteers. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2007, Abstract A72

  111. A Study to Determine the Activity of SCH 717454 in Subjects With Relapsed Osteosarcoma or Ewing’s Sarcoma (Study P04720). http://clinicaltrials.gov/show/NCT00617890. Accessed on 28 September 2008

  112. A Study to Determine the Activity of SCH 717454 in Subjects With Relapsed or Recurrent Colorectal Cancer (Study P04721AM1). http://clinicaltrials.gov/show/NCT00551213. Accessed on 28 September 2008

  113. Hariharan K, Dong J; Demarest S et al (2007) BIIB022, a fully human nonglycosylated γ4P antibody targeting IGF-1R for cancer therapy. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2007, abstract B210

  114. Dong J, Tamraz S, Berquist L et al (2008) BIIB022, a human antibody targeting human insulin-like growth factor-1 receptor (IGF-1R), enhances the antitumor activities of Tarceva in non small cell lung carcinoma (NSCLC) and Rapamycin in sarcoma cell lines. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008. Abstr. 4002.

  115. Cortes J, Paquette R, Talpaz M et al (2008) Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation. ASH Annual Meeting Abstracts Blood 112:3232

    Google Scholar 

  116. Smith DC, C. Britten C, Clary DO et al (2009) A phase I study of XL228, a potent IGF1R/AURORA/SRC inhibitor, in patients with solid tumors or hematologic malignancies. J Clin Oncol 27(15S): abstract 3512

  117. Harzstark AL, Ryan C, Diamond M et al (2007) A phase I trial of nordihydroguareacetic acid (NDGA) in patients with non-metastatic prostate cancer and rising PSA. J Clin Oncol 25(18S) abstract 15500

    Google Scholar 

  118. Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer. http://clinicaltrials.gov/show/NCT00678015. Accessed on 28 Sept 2008

  119. Werner H, Woloschak M, Adamo M et al (1989) Developmental regulation of the rat insulin-like growth factor I receptor gene. Proc Natl Acad Sci U S A 86(19):7451–7455

    Article  CAS  PubMed  Google Scholar 

  120. Benyoucef S, Surinya KH, Hadaschik D, Siddle K (2007) Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11sequence to ligand binding and receptor activation. Biochem J 403:603–613

    Article  CAS  PubMed  Google Scholar 

  121. Lammers R, Gray A, Schlessinger J, Ullrich A (1989) Differential signalling potential of insulin- and IGF-1-receptor cytoplasmic domains. EMBO J 8:1369–1375

    CAS  PubMed  Google Scholar 

  122. Belfiore A (2007) The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 13:671–686

    Article  CAS  PubMed  Google Scholar 

  123. Gualberto A, Pollak M (2009) Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology. Curr Drug Targets. Oct 1 epublication

  124. Gualberto A, Karp DD (2009) Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. Clin Lung Cancer 10(4):273–280

    Article  CAS  PubMed  Google Scholar 

  125. Olmos D, Molife R, Okuno S, Worden F, Hammer G, Yap T et al (2007) Safety, tolerability and preliminary efficacy of the anti-IGFIR monoclonal antibody CP-751,871 in patients with sarcomas and adrenocortical tumors. Presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting, San Francisco, USA, 22–26, October 2007

  126. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337–345

    Article  CAS  PubMed  Google Scholar 

  127. Thomson S, Buck E, Petti F et al (2005) Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65:9455–9462

    Article  CAS  PubMed  Google Scholar 

  128. Pandini G, Wurch T, Akla B et al (2007) Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer 43:1318–1327

    Article  CAS  PubMed  Google Scholar 

  129. Huang FHW, Hafezi R, Han X et al (2007) Identification of sensitivity markers for BMS-536924, an inhibitor for insulin-like growth factor-1 receptor. ASCO Ann Meet Proc 2007. J Clin Oncol 25:3506

    Google Scholar 

  130. Pollak MNLM, Lipton A, Demers L (2007) Pharmacodynamic properties of the anti-IGF-IR monoclonal antibody CP-751,871 in cancer patients. ASCO Ann Meet Proc 2007. J Clin Oncol 25:3587

    Article  Google Scholar 

  131. Scotlandi K (2006) Targeted therapies in Ewing’s sarcoma. Adv Exp Med Biol 587:13–22

    CAS  PubMed  Google Scholar 

  132. Ji QS, Mulvihill M, Franklin M et al (2007) Properties of small molecule IGF-IR kinase inhibitors in preclinical models. AACR Annual Meeting 2007, Los Angeles (CA): abstract 30.9

Download references

Acknowledgements

We thank Carol Pearce for her editorial assistance.

Conflict of interest statement

No funds were received in support of this study.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, University of Cagliari, 09042, Cagliari, Italy

    Francesco Atzori, Maria Teresa Ionta & Bruno Massidda

  2. Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Tiffany A. Traina

Authors
  1. Francesco Atzori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tiffany A. Traina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Teresa Ionta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bruno Massidda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Atzori.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Atzori, F., Traina, T.A., Ionta, M.T. et al. Targeting insulin-like growth factor type 1 receptor in cancer therapy. Targ Oncol 4, 255–266 (2009). https://doi.org/10.1007/s11523-009-0123-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-009-0123-z

Keywords

Search

Navigation